# US 2024/0398938 A1 · Hepatitis C Virus Peptide Compositions and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0398938 A1
- Document ID: US20240398938A1
- Status: Published application
- Kind: A1
- Application number: 18/740,380
- Filed: 2024-06-11
- Published: 2024-12-05
- Earliest claimed: 2018-03-16
- Assignees: The Governors of the University of Alberta
- Applicants: The Governors of the University of Alberta
- Inventors: Michael Houghton; Abdolamir Landi; Michael Logan; John L. Law; Chao Chen; Darren Hockman
- Web page: https://patentgrep.com/patent/US20240398938A1

## CPC

- A61K 39/29: Hepatitis virus
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/05: Epstein-Barr virus
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.

## Claims

### Claim 1

An immunogenic composition comprising:
a) one or more T-cell epitope polypeptides selected from:
i) a TP35-NS3 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to:
KSTKVPX1AYX2X3QGYX4VLVLNPSVAATLGFGX5X6X7SX8 (SEQ ID NO:134), wherein X1 is A or V; X2 is A or V; X3 is A or S; X4 is K or N; X5 is A or S; X6 is Y or F; X7 is M or L; and X5 is K or R, wherein the TP35-NS3 T-cell epitope polypeptide has a length of from 28 amino acids to 35 amino acids; and
ii) a TP50C T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to:
GVYX1LPRRGPRLGVRX2TRKX3SERSQPRGRRQX4PKX5X6X7X8X9GX10X11WX12X13PGYP (SEQ ID NO:149), where X1 is L or V; X2 is A or G; X3 is T or S; X4 is P or R; X5 is A or D; X6 is R or A; X7 is R, Q, or S; X8 is S or P; X9 is E, T, or Q; X10 is R or K; X11 is S, T, H, or A; X12 is A or G; and X13 is Q or K, wherein the TP50C T-cell epitope polypeptide has a length of from 40 amino acids to 50 amino acids;
iii) a TP23 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: DVVVX1X2TDALMTGX3TGDFDSVID (SEQ ID NO:171), wherein X1 is V or C; X2 is A or S; and X3 is F or Y, wherein the TP23 T-cell epitope polypeptide has a length of from 18 amino acids to 23 amino acids;
iv) a TP27 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3X4KGGRHLIFCHSKKKCDEX5AX6X7LX8 (SEQ ID NO:189), where X1 is L or I; X2 is E, A, S, V, or Q; X3 is Q, T, Y, F, or L; X4 is I or L; X5 is L or I; X6 is A, K, or S; X7 is K, Q, or A; and X8 is T, R, or S, wherein the TP27 T-cell epitope polypeptide has a length of from 22 amino acids to 27 amino acids;
v) a TP35-NS4 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3RHX4GX5X6EGX7X8QWMNRLIAFASRGNHVX9PTHYX10 (SEQ ID NO:204), wherein X1 is I or V; X2 is L or I; X3 is R or K; X4 is V, I, or T; X5 is P, Q, or T; X6 is G, A, or S; X7 is A or V; X8 is V or T; X9 is S or A; and X10 is V or I, wherein the TP35-NS4 T-cell epitope polypeptide has a length of from 28 amino acids to 35 amino acids;
vi) a TP42 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3GEIPFYGX4AIPX5X6X7X8KGGRHLIFCHSKKKCDEX9AX10X11LX12X13(K)n (SEQ ID NO:229), where X1 is G, P, or S; X2 is T, N, Q, H, or S; X3 is E, T, or D; X4 is K or R; X5 is L or I; X6 is E, A, S, or Q; X7 is Q, T, Y, F, or L; X8 is I or L; X9 is L or I; X10 is A, K, or S; X11 is K, Q, or A; X12 is T, R, or S; and X13 is G or S, wherein n is an integer from 2 to 10, and wherein the TP42 T-cell epitope polypeptide has a length of from 34 amino acids to 52 amino acids;
vii) a TP45 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2AVAX3YRGX4DVX5X6IPX7X8GDVVVX9X10TDALMTGX11TGDFDSVIDX12X13X14(K)n (SEQ ID NO:249), wherein X1 is L or V; X2 is N or T; X3 is Y or F; X4 is L or V; X5 is S or A; X6 is V or I; X7 is T or A; X8 is S, Q, or T; X9 is V or C; X10 is A or S; X11 is F or Y; X12 is C or K; X13 is N or K; and X14 is V or K, wherein n is an integer from 2 to 10, and wherein the TP45 T-cell epitope polypeptide has a length of from 36 amino acids to 55 amino acids; and
viii) a TP48 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3RHX4GX5X6EGX7X5QWMNRLIAFASRGNHVX9PTHYX10Xu11X12X13DAX14X15X16VX17X18X19L(K)n (SEQ ID NO:255), wherein X1 is I or V; X2 is L or I; X3 is R or K; X4 is V, I, or T; X5 is P, Q, or T; X6 is G, A, or S; X7 is A or V; X8 is V or T; X9 is S or A; X10 is V or I; X11 is P, T, A, or Q, X12 is E or D; X13 is S, T, or D; X14 is S or A; X15 is A, Q, R, or K; X16 is R, K, or X; X17 is T or M; X18 is Q, A, T, or G; and X19 is I, L, or V, wherein n is an integer from 2 to 10, and wherein the TP48 T-cell epitope polypeptide has a length of from 38 amino acids to 58 amino acids;
ix) a TP33 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: HSKKKCDELAX1X2LX3X4X5GX6NAVAYYRGLDVSX7IP (SEQ ID NO:287), where X1 is A or S; X2 is K or A; X3 is V, S, R, or T; X4 is A or G; X5 is L or M; X6 is I, L, or V; and X7 is V or I; wherein the TP33 T-cell epitope polypeptide has a length of from 30 amino acids to 36 amino acids;
x) a TP42-2 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: KGGRHLIFCHSKKKCDELAX1X2LX3X4X5GX6NAVAYYRGLDVSX7IP (SEQ ID NO:292), where X1 is A or S; X2 is K or A; X3 is V, S, R, or T; X4 is A or G; X5 is L or M; X6 is I, L, or V; and X7 is V or I; wherein the TP42-2 T-cell epitope polypeptide has a length of from 38 amino acids to 46 amino acids; and
b) an immune-stimulating amount of an adjuvant.

### Claim at position 2

-24. (canceled)

### Claim 25 (depends on 1)

A method of inducing an immune response in an individual to a hepatitis C virus (HCV) polypeptide, the method comprising administering to the individual:
a) an effective amount of the immunogenic composition of claim 1; or
b) one or more nucleic acids comprising nucleotide sequences encoding the T-cell epitope polypeptide(s) and/or the HCV E1/E2 heterodimeric polypeptide.

### Claim at position 4

-30. (canceled)

### Claim 31

A composition comprising one or more nucleic acids selected from the group consisting of:
i) a nucleic acid comprising a nucleotide sequence encoding a TP35-NS3 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to:
KSTKVPX1AYX2X3QGYX4VLVLNPSVAATLGFGX5X6X7SX8 (SEQ ID NO:134), wherein X1 is A or V; X2 is A or V; X3 is A or S; X4 is K or N; X5 is A or S; X6 is Y or F; X7 is M or L; and X8 is K or R, wherein the TP35-NS3 T-cell epitope polypeptide has a length of from 28 amino acids to 35 amino acids; and
ii) a nucleic acid comprising a nucleotide sequence encoding a TP50C T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to:
GVYX1LPRRGPRLGVRX2TRKX3SERSQPRGRRQX4IPKX5X6X7X8X9GX10X11WX12X13PGYP (SEQ ID NO:149), where X1 is L or V; X2 is A or G; X3 is T or S; X4 is P or R; X5 is A or D; X6 is R or A; X7 is R, Q, or S; X8 is S or P; X9 is E, T, or Q; X10 is R or K; X11 is S, T, H, or A; X12 is A or G; and X13 is Q or K, wherein the TP50C T-cell epitope polypeptide has a length of from 40 amino acids to 50 amino acids;
iii) a nucleic acid comprising a nucleotide sequence encoding a TP23 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: DVVVX1X2TDALMTGX3TGDFDSVID (SEQ ID NO:171), wherein X1 is V or C; X2 is A or S; and X3 is F or Y, wherein the TP23 T-cell epitope polypeptide has a length of from 18 amino acids to 23 amino acids;
iv) a nucleic acid comprising a nucleotide sequence encoding a TP27 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3X4KGGRHLIFCHSKKKCDEX5AX6X7LX8 (SEQ ID NO:189), where X1 is L or I; X2 is E, A, S, V, or Q; X3 is Q, T, Y, F, or L; X4 is I or L; X5 is L or I; X6 is A, K, or S; X7 is K, Q, or A; and X8 is T, R, or S, wherein the TP27 T-cell epitope polypeptide has a length of from 22 amino acids to 27 amino acids;
v) a nucleic acid comprising a nucleotide sequence encoding a TP35-NS4 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3RHX4GX5X6EGX7X8QWMNRLIAFASRGNHVX9PTHYX10 (SEQ ID NO:204), wherein X1 is I or V; X2 is L or I; X3 is R or K; X4 is V, I, or T; X5 is P, Q, or T; X6 is G, A, or S; X7 is A or V; X8 is V or T; X9 is S or A; and X10 is V or I, wherein the TP35-NS4 T-cell epitope polypeptide has a length of from 28 amino acids to 35 amino acids;
vi) a nucleic acid comprising a nucleotide sequence encoding a TP42 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3GEIPFYGX4AIPX5X6X7X8KGGRHLIFCHSKKKCDEX9AX10X11LX12X13(K)n (SEQ ID NO:229), where X1 is G, P, or S; X2 is T, N, Q, H, or S; X3 is E, T, or D; X4 is K or R; X5 is L or I; X6 is E, A, S, or Q; X7 is Q, T, Y, F, or L; X8 is I or L; X9 is L or I; X10 is A, K, or S; Xu is K, Q, or A; X12 is T, R, or S; and X13 is G or S, wherein n is an integer from 2 to 10, and wherein the TP42 T-cell epitope polypeptide has a length of from 34 amino acids to 52 amino acids;
vii) a nucleic acid comprising a nucleotide sequence encoding a TP45 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2AVAX3YRGX4DVX5X6IPX7X8GDVVVX9X10TDALMTGX11TGDFDSVIDX12X13X14(K)n (SEQ ID NO:249), wherein X1 is L or V; X2 is N or T; X3 is Y or F; X4 is L or V; X5 is S or A; X6 is V or I; X7 is T or A; X8 is S, Q, or T; X9 is V or C; X10 is A or S; X11 is F or Y; X12 is C or K; X13 is N or K; and X14 is V or K, wherein n is an integer from 2 to 10, and wherein the TP45 T-cell epitope polypeptide has a length of from 36 amino acids to 55 amino acids; and
viii) a nucleic acid comprising a nucleotide sequence encoding a TP48 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3RHX4GX5X6EGX7X8QWMNRLIAFASRGNHVX9PTHYX10X11X12X13DAX14X15X16VX17X18X19L(K)n (SEQ ID NO:255), wherein X1 is I or V; X2 is L or I; X3 is R or K; X4 is V, I, or T; X5 is P, Q, or T; X6 is G, A, or S; X7 is A or V; X8 is V or T; X9 is S or A; X10 is V or I; X11 is P, T, A, or Q, X12 is E or D; X13 is S, T, or D; X14 is S or A; X15 is A, Q, R, or K; X16 is R, K, or X; X17 is T or M; X18 is Q, A, T, or G; and X19 is I, L, or V, wherein n is an integer from 2 to 10, and wherein the TP48 T-cell epitope polypeptide has a length of from 38 amino acids to 58 amino acids;
ix) a nucleic acid comprising a nucleotide sequence encoding a TP33 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: HSKKKCDELAX1X2LX3X4X5GX6NAVAYYRGLDVSX7IP (SEQ ID NO:287), where X1 is A or S; X2 is K or A; X3 is V, S, R, or T; X4 is A or G; X5 is L or M; X6 is I, L, or V; and X7 is V or I; wherein the TP33 T-cell epitope polypeptide has a length of from 30 amino acids to 36 amino acids;
x) a nucleic acid comprising a nucleotide sequence encoding a TP42-2 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: KGGRHLIFCHSKKKCDELAX1X2LX3X4X5GX6NAVAYYRGLDVSX7IP (SEQ ID NO:292), where X1 is A or S; X2 is K or A; X3 is V, S, R, or T; X4 is A or G; X5 is L or M; X6 is I, L, or V; and X7 is V or I; wherein the TP42-2 T-cell epitope polypeptide has a length of from 38 amino acids to 46 amino acids;
xi) a TP42 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3GEIPFYGX4AIPX5X6X7X8KGGRHLIFCHSKKKCDEX9AX10X11LX12X13 (SEQ ID NO:232), where X1 is G, P, or S; X2 is T, N, Q, H, or S; X3 is E, T, or D; X4 is K or R; X5 is L or I; X6 is E, A, S, or Q; X7 is Q T, Y, F, or L; X8 is I or L; X9 is L or I; X10 is A, K, or S; X11 is K, Q, or A; X12 is T, R, or S; and X13 is G or S, and wherein the TP42 T-cell epitope polypeptide has a length of from 33 amino acids to 42 amino acids;
xii) a TP45 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2AVAX3YRGX4DVX5X6IPX7X8GDVVVX9X10TDALMTGX11TGDFDSVIDX12X13X14 (SEQ ID NO:252), where X1 is L or V; X2 is N or T; X3 is Y or F; X4 is L or V; X5 is S or A; X6 is V or I; X7 is T or A; X8 is S, Q, or T; X9 is V or C; X10 is A or S; X11 is F or Y; X12 is C or K; X13 is N or K; and X14 is V or K, and wherein the TP45 T-cell epitope polypeptide has a length of from 36 amino acids to 55 amino acids; and
xiii a TP48 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3RHX4GX5X6EGX7X8QWMNRLIAFASRGNHVX9PTHYX10X11X12X13DAX14X15X16VX17X18X19L (SEQ ID NO:266), where X1 is I or V; X2 is L or I; X3 is R or K; X4 is V, I, or T; X5 is P, Q, or T; X6 is G, A, or S; X7 is A or V; X8 is V or T; X9 is S or A; X10 is V or I; X11 is P, T, A, or Q, X12 is E or D; X13 is S, T, or D; X14 is S or A; X15 is A, Q, R, or K; X16 is R, K, or X; X17 is T or M; X18 is Q, A, T, or G; and X19 is I, L, or V, and wherein the TP48 T-cell epitope polypeptide has a length of from 38 amino acids to 58 amino acids;.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the one or more nucleic acids are one or more mRNA molecules.

### Claim 33 (depends on 31)

The composition of claim 31, wherein the one or more mRNA molecules are formulated with a liposome.

### Claim 34 (depends on 31)

The composition of claim 31, wherein the composition comprises one or more nucleic acids comprising nucleotide sequences encoding a hepatitis C virus (HCV) E1 polypeptide and/or an HCV E2 polypeptide.

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 31)

A method of inducing an immune response in an individual, the method comprising administering to the individual a composition of claim 31.

### Claim 38 (depends on 35)

The method of claim 35, wherein said administering comprises:
a) administering a priming dose comprising the composition; and
b) administering a boosting dose comprising the composition.

### Claim 39

A nucleic acid comprising a nucleotide sequence encoding a fusion polypeptide comprising from 2 to 10 polypeptides selected from the group consisting of:
i) a TP35-NS3 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to:
KSTKVPX1AYX2X3QGYX4VLVLNPSVAATLGFGX5X6X7SX8 (SEQ ID NO:134), wherein X1 is A or V; X2 is A or V; X3 is A or S; X4 is K or N; X5 is A or S; X6 is Y or F; X7 is M or L; and X8 is K or R, wherein the TP35-NS3 T-cell epitope polypeptide has a length of from 28 amino acids to 35 amino acids; and
ii) a TP50C T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to:
GVYX1LPRRGPRLGVRX2TRKX3SERSQPRGRRQX4IPKX5X6X7X5X9GX10X11WX12X13PGYP (SEQ ID NO:149), where X1 is L or V; X2 is A or G; X3 is T or S; X4 is P or R; X5 is A or D; X6 is R or A; X7 is R, Q, or S; X8 is S or P; X9 is E, T, or Q; X10 is R or K; X11 is S, T, H, or A; X12 is A or G; and X13 is Q or K, wherein the TP50C T-cell epitope polypeptide has a length of from 40 amino acids to 50 amino acids;
iii) a TP23 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: DVVVX1X2TDALMTGX3TGDFDSVID (SEQ ID NO:171), wherein X1 is V or C; X2 is A or S; and X3 is F or Y, wherein the TP23 T-cell epitope polypeptide has a length of from 18 amino acids to 23 amino acids;
iv) a TP27 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3X4KGGRHLIFCHSKKKCDEX5AX6X7LX8 (SEQ ID NO:189), where X1 is L or I; X2 is E, A, S, V, or Q; X3 is Q, T, Y, F, or L; X4 is I or L; X5 is L or I; X6 is A, K, or S; X7 is K, Q, or A; and X8 is T, R, or S, wherein the TP27 T-cell epitope polypeptide has a length of from 22 amino acids to 27 amino acids;
v) a TP35-NS4 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3RHX4GX5X6EGX7X8QWMNRLIAFASRGNHVX9PTHYX10 (SEQ ID NO:204), wherein X1 is I or V; X2 is L or I; X3 is R or K; X4 is V, I, or T; X5 is P, Q, or T; X6is G, A, or S; X7is A or V; X8 is V or T; X9 is S or A; and X10 is V or I, wherein the TP35-NS4 T-cell epitope polypeptide has a length of from 28 amino acids to 35 amino acids;
vi) a TP42 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3GEIPFYGX4AIPX5X6X7X8KGGRHLIFCHSKKKCDEX9AX10X11LX12X13(K)n (SEQ ID NO:229), where X1 is G, P, or S; X2 is T, N, Q, H, or S; X3 is E, T, or D; X4 is K or R; X5 is L or I; X6 is E, A, S, or Q; X7 is Q, T, Y, F, or L; X8 is I or L; X9 is L or I; X10 is A, K, or S; X11 is K, Q, or A; X12 is T, R, or S; and X13 is G or S, wherein n is an integer from 2 to 10, and wherein the TP42 T-cell epitope polypeptide has a length of from 34 amino acids to 52 amino acids;
vii) a TP45 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2AVAX3YRGX4DVX5X6IPX7X8GDVVVX9X10TDALMTGX11TGDFDSVIDX12X13X14(K)n (SEQ ID NO:249), wherein X1 is L or V; X2 is N or T; X3 is Y or F; X4 is L or V; X5 is S or A; X6 is V or I; X7 is T or A; X8 is S, Q, or T; X9 is V or C; X10 is A or S; X11 is F or Y; X12 is C or K; X13 is N or K; and X14 is V or K, wherein n is an integer from 2 to 10, and wherein the TP45 T-cell epitope polypeptide has a length of from 36 amino acids to 55 amino acids; and
viii) a TP48 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3RHX4GX5X6EGX7X8QWMNRLIAFASRGNHVX9PTHYX10X11X12X13DAX14X15X16VX17X18X19L(K)n (SEQ ID NO:255), wherein X1 is I or V; X2 is L or I; X3 is R or K; X4 is V, I, or T; X5 is P, Q, or T; X6 is G, A, or S; X7 is A or V; X8 is V or T; X9 is S or A; X10 is V or I; X11 is P, T, A, or Q, X12 is E or D; X13 is S, T, or D; X14 is S or A; X15 is A, Q, R, or K; X16 is R, K, or X; X17 is T or M; X18 is Q, A, T, or G; and X19 is I, L, or V, wherein n is an integer from 2 to 10, and wherein the TP48 T-cell epitope polypeptide has a length of from 38 amino acids to 58 amino acids;
ix) a TP33 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: HSKKKCDELAX1X2LX3X4X5GX6NAVAYYRGLDVSX7IP (SEQ ID NO:287), where X1 is A or S; X2 is K or A; X3 is V, S, R, or T; X4 is A or G; X5 is L or M; X6 is I, L, or V; and X7 is V or I; wherein the TP33 T-cell epitope polypeptide has a length of from 30 amino acids to 36 amino acids;
x) a TP42-2 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: KGGRHLIFCHSKKKCDELAX1X2LX3X4X5GX6NAVAYYRGLDVSX7IP (SEQ ID NO:292), where X1 is A or S; X2 is K or A; X3 is V, S, R, or T; X4 is A or G; X5 is L or M; X6 is I, L, or V; and X7 is V or I; wherein the TP42-2 T-cell epitope polypeptide has a length of from 38 amino acids to 46 amino acids;
xi) a TP42 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3GEIPFYGX4AIPX5X6X7X8KGGRHLIFCHSKKKCDEX9AX10X11LX12X13 (SEQ ID NO:232), where X1 is G, P, or S; X2 is T, N, Q, H, or S; X3 is E, T, or D; X4 is K or R; X5 is L or I; X6 is E, A, S, or Q; X7 is Q T, Y, F, or L; X8 is I or L; X9 is L or I; X10 is A, K, or S; X11 is K, Q, or A; X12 is T, R, or S; and X13 is G or S, and wherein the TP42 T-cell epitope polypeptide has a length of from 33 amino acids to 42 amino acids;
xii) a TP45 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2AVAX3YRGX4DVX5X6IPX7X8GDVVVX9X10TDALMTGX11TGDFDSVIDX12X13X14 (SEQ ID NO:252), where X1 is L or V; X2 is N or T; X3 is Y or F; X4 is L or V; X5 is S or A; X6 is V or I; X7 is T or A; X8 is S, Q, or T; X9 is V or C; X10 is A or S; X11 is F or Y; X12 is C or K; X13 is N or K; and X14 is V or K, and wherein the TP45 T-cell epitope polypeptide has a length of from 36 amino acids to 55 amino acids; and
xiii a TP48 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: X1X2X3RHX4GX5X6EGX7X8QWMNRLIAFASRGNHVX9PTHYX10X11X12X13DAX14X15X16VX17X18X19L (SEQ ID NO:266), where X1 is I or V; X2 is L or I; X3 is R or K; X4 is V, I, or T; X5 is P, Q, or T; X6 is G, A, or S; X7 is A or V; X8 is V or T; X9 is S or A; X10 is V or I; X11 is P, T, A, or Q, X12 is E or D; X13 is S, T, or D; X14 is S or A; X15 is A, Q, R, or K; X16 is R, K, or X; X17 is T or M; X18 is Q, A, T, or G; and X19 is I, L, or V, and wherein the TP48 T-cell epitope polypeptide has a length of from 38 amino acids to 58 amino acids.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the nucleic acid is an mRNA

### Claim 41 (depends on 40)

The composition of claim 40, wherein the mRNA is formulated with a liposome.

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44 (depends on 39)

A method of inducing an immune response in an individual, the method comprising administering to the individual a composition of claim 39.

### Claim 45 (depends on 39)

The method of claim 39, wherein said administering comprises:
a) administering a priming dose comprising the composition; and
b) administering a boosting dose comprising the composition.

### Claim 46 (depends on 1)

The immunogenic composition of claim 1, wherein the composition comprises 2, 3, 4, or 5 different T-cell epitope polypeptides.

### Claim 47 (depends on 46)

The immunogenic composition of claim 46, wherein the composition comprises:
(a) a TP50C T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to:
GVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPKARRSEGRSWAQPGYP (SEQ ID NO:148), wherein the TP50C T-cell epitope polypeptide has a length of from 40 amino acids to 50 amino acids; and
(b) a TP48 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: ILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTQIL (SEQ ID NO:268), wherein the T-cell epitope polypeptide has a length of from 45 amino acids to 55 amino acids.

### Claim 48 (depends on 47)

The immunogenic composition of claim 47, wherein the composition further comprises:
(c) a TP35-NS4 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: ILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYV (SEQ ID NO:203), wherein the TP35-NS4 T-cell epitope polypeptide has a length of from 28 amino acids to 35 amino acids.

### Claim 49 (depends on 47)

The immunogenic composition of claim 47, wherein the composition further comprises:
(c) a TP27 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: LEQIKGGRHLIFCHSKKKCDELAAKLT (SEQ ID NO:188), wherein the TP27 T-cell epitope polypeptide has a length of from 22 amino acids to 27 amino acids.
